Legend Biotech Corp (LEGN)
Data as of , from SEC Form 4 filings.
See up to 3 months of LEGN. The 7-day demo opens the 1M and 3M ranges and puts LEGN on your watchlist.
Start 7-day demoLatest LEGN insider trades
- Corazon (Corsee) D. Sanders - DirectorOpen-market sale$259K
- Carlos E. Santos - OfficerOpen-market sale$50K
Patrick John CaseyOpen-market sale$89K
Ying Huang - OfficerOpen-market sale$82K- Ying Huang - OfficerOpen-market sale$87K
- Peter Salovey - DirectorGrant or award28,330 sh
- Tomas J. Heyman - DirectorGrant or award20,986 sh
- Li Mao - DirectorGrant or award20,986 sh
About Legend Biotech Corp (LEGN)
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
- 3,200
- 2020
- XNAS
LEGN Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 2 | 32,800 | $309K |
| Grant or award | 9 | 1,297,048 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
LEGN insider transactions (Form 4)
1514 Form 4 filings on record, the earliest from Mar 27, 2026, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Corazon (Corsee) D. Sanders - Director | Open-market sale | Ordinary Shares | 27,370 | $9.46 footnote F2 | $259K | |
| ||||||
| Peter Salovey - Director | Grant or award | Ordinary Shares | 28,330 footnote F2 | $0.00 | - | |
| ||||||
| Tomas J. Heyman - Director | Grant or award | Ordinary Shares | 20,986 footnote F2 | $0.00 | - | |
| ||||||
| Li Mao - Director | Grant or award | Ordinary Shares | 20,986 footnote F2 | $0.00 | - | |
| ||||||
| Patrick John Casey - Director | Grant or award | Ordinary Shares | 20,986 footnote F2 | $0.00 | - | |
| ||||||
| Darren Xiaohui Ji - Director | Grant or award | Ordinary Shares | 28,330 footnote F2 | $0.00 | - | |
| ||||||
| Corazon (Corsee) D. Sanders - Director | Grant or award | Ordinary Shares | 20,986 footnote F2 | $0.00 | - | |
| ||||||
| Carlos E. Santos - Officer | Grant or award | Ordinary Shares | 19,676 | $0.00 | - | |
| Carlos E. Santos - Officer | Open-market sale | Ordinary Shares | 5,430 footnote F2 | $9.14 footnote F3 | $50K | |
| ||||||
| Ingrid Zhang - Officer | Grant or award | Ordinary Shares | 1,131,860 footnote F2 | $0.00 | - | |
| ||||||
| Alan Bash - Officer | Grant or award | Ordinary Shares | 4,908 footnote F2 | $0.00 | - | |
| ||||||
| Patrick John Casey | Open-market sale | Ordinary Shares | 6,000 | $14.80 footnote F2 | $89K | |
| ||||||
| Ying Huang - Officer | Gift | Ordinary Shares | 3,382 | $0.00 | - | |
| Ying Huang - Officer | Open-market sale | Ordinary Shares | 5,566 | $14.78 footnote F3 | $82K | |
| ||||||
| Ying Huang - Officer | Open-market sale | Ordinary Shares | 9,936 | $8.77 footnote F3 | $87K | |
| ||||||
Recent LEGN Form 144 notices of proposed sale
3An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| Sanders Corazon (Corsee) D. | Director | 13,685 | $259K | View on EDGAR | |
| Santos Carlos E | Officer | 2,715 | $51K | View on EDGAR | |
| Huang Ying | Former Officer & Director | 69,812 | $1.30M | View on EDGAR |
LEGN insider trading FAQ
What is the latest insider trade for LEGN?
Legend Biotech Corp (LEGN) had 10 insider filings in the last 90 days, with the most recent on 2026-10-01. The full record for LEGN runs to 14 Form 4 filings, the earliest from 2026-03-27. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying LEGN stock?
No insider purchases of LEGN were filed in the last 90 days.
How many insiders are selling LEGN stock?
2 insider sales of LEGN were filed in the last 90 days, totaling $309K.
Where can I see LEGN SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects LEGN Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Corazon (Corsee) D. Sanders view on EDGAR
- - Peter Salovey view on EDGAR
- - Tomas J. Heyman view on EDGAR
- - Li Mao view on EDGAR
- - Patrick John Casey view on EDGAR
- - Darren Xiaohui Ji view on EDGAR
- - Corazon (Corsee) D. Sanders view on EDGAR
- - Carlos E. Santos view on EDGAR
- - Ingrid Zhang view on EDGAR
- - Alan Bash view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where LEGN's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow LEGN with a 7-day demo
- LEGN on your watchlist
- Every LEGN Form 4 filing on record
- Up to 3 months of LEGN price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.